MBX Biosciences, Inc., a startup co-founded by Gill Chair Richard DiMarchi, recently raised $163.2 million in its U.S. initial public offering. The company aims to help individuals with endocrine and metabolic diseases such as chronic hypoparathyroidism live healthier lives.
Dr. Shafer, Professor and newly appointed Gill Chair, joins IU to expand his research into what makes our internal clocks tick.
IU Vice President for Research Russell Mumper outlines recent changes that will better support researchers and meet our ambitious goals for the year.
Dr. DiMarchi to be honored for breakthrough research in obesity drug discovery.
Dr. Lu and her lab identify an enzyme that can play a critical role in fending off neurodegenerative diseases.
Gill Institute researchers have potentially discovered a new way to block the brain’s reward response to opioids, reducing their potential for addiction without reducing their therapeutic aspects.
